vs
Clearfield, Inc.（CLFD）与Day One Biopharmaceuticals, Inc.（DAWN）财务数据对比。点击上方公司名可切换其他公司
Day One Biopharmaceuticals, Inc.的季度营收约是Clearfield, Inc.的1.2倍（$39.8M vs $34.3M），Clearfield, Inc.净利率更高（-1.8% vs -49.6%，领先47.8%），Clearfield, Inc.同比增速更快（-3.2% vs -57.6%）
Clearfield, Inc.总部位于美国明尼苏达州明尼阿波利斯市，是一家专注于光纤产品研发生产的企业，其产品主要应用于光纤通信网络建设领域，为通信基础设施部署提供相关硬件支撑。
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
CLFD vs DAWN — 直观对比
营收规模更大
DAWN
是对方的1.2倍
$34.3M
营收增速更快
CLFD
高出54.4%
-57.6%
净利率更高
CLFD
高出47.8%
-49.6%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.3M | $39.8M |
| 净利润 | $-614.0K | $-19.7M |
| 毛利率 | 33.2% | — |
| 营业利润率 | -5.3% | -60.9% |
| 净利率 | -1.8% | -49.6% |
| 营收同比 | -3.2% | -57.6% |
| 净利润同比 | 67.8% | -153.3% |
| 每股收益（稀释后） | $-0.04 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFDDAWN
| Q4 25 | $34.3M | — | ||
| Q3 25 | $23.4M | $39.8M | ||
| Q2 25 | $49.9M | $33.9M | ||
| Q1 25 | $47.2M | $30.8M | ||
| Q4 24 | $29.7M | — | ||
| Q3 24 | $5.6M | $93.8M | ||
| Q2 24 | $48.8M | — | ||
| Q1 24 | $36.9M | $0 |
净利润CLFDDAWN
| Q4 25 | $-614.0K | — | ||
| Q3 25 | $-9.1M | $-19.7M | ||
| Q2 25 | $1.6M | $-30.3M | ||
| Q1 25 | $1.3M | $-36.0M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | — | $37.0M | ||
| Q2 24 | $-447.0K | — | ||
| Q1 24 | $-5.9M | $-62.4M |
毛利率CLFDDAWN
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
营业利润率CLFDDAWN
| Q4 25 | -5.3% | — | ||
| Q3 25 | 10.3% | -60.9% | ||
| Q2 25 | 3.0% | -103.1% | ||
| Q1 25 | 0.6% | -133.5% | ||
| Q4 24 | -6.9% | — | ||
| Q3 24 | — | 31.6% | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | -26.4% | — |
净利率CLFDDAWN
| Q4 25 | -1.8% | — | ||
| Q3 25 | -38.8% | -49.6% | ||
| Q2 25 | 3.2% | -89.4% | ||
| Q1 25 | 2.8% | -117.0% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | — | 39.5% | ||
| Q2 24 | -0.9% | — | ||
| Q1 24 | -16.0% | — |
每股收益（稀释后）CLFDDAWN
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.65 | $-0.19 | ||
| Q2 25 | $0.11 | $-0.29 | ||
| Q1 25 | $0.09 | $-0.35 | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | — | $0.38 | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.40 | $-0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.4M | $451.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $249.7M | $450.9M |
| 总资产 | $268.1M | $513.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLFDDAWN
| Q4 25 | $96.4M | — | ||
| Q3 25 | $106.0M | $451.6M | ||
| Q2 25 | $117.2M | $453.1M | ||
| Q1 25 | $112.0M | $473.0M | ||
| Q4 24 | $113.0M | — | ||
| Q3 24 | $129.0M | $558.4M | ||
| Q2 24 | $123.8M | — | ||
| Q1 24 | $142.9M | $317.9M |
总债务CLFDDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
股东权益CLFDDAWN
| Q4 25 | $249.7M | — | ||
| Q3 25 | $256.2M | $450.9M | ||
| Q2 25 | $264.5M | $460.8M | ||
| Q1 25 | $265.9M | $479.5M | ||
| Q4 24 | $267.4M | — | ||
| Q3 24 | $275.8M | $555.5M | ||
| Q2 24 | $274.6M | — | ||
| Q1 24 | $279.2M | $296.8M |
总资产CLFDDAWN
| Q4 25 | $268.1M | — | ||
| Q3 25 | $306.2M | $513.8M | ||
| Q2 25 | $314.7M | $519.0M | ||
| Q1 25 | $310.9M | $534.4M | ||
| Q4 24 | $303.2M | — | ||
| Q3 24 | $315.3M | $600.8M | ||
| Q2 24 | $318.1M | — | ||
| Q1 24 | $315.4M | $326.6M |
负债/权益比CLFDDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 2.9% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLFDDAWN
| Q4 25 | $-1.4M | — | ||
| Q3 25 | — | $-5.8M | ||
| Q2 25 | $7.9M | $-24.8M | ||
| Q1 25 | $3.0M | $-59.0M | ||
| Q4 24 | $7.2M | — | ||
| Q3 24 | $22.2M | $50.8M | ||
| Q2 24 | $4.0M | — | ||
| Q1 24 | $-5.7M | $-49.7M |
自由现金流CLFDDAWN
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.5M | $-24.8M | ||
| Q1 25 | $654.0K | $-59.3M | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $18.2M | $50.0M | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $-7.7M | — |
自由现金流率CLFDDAWN
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.1% | -73.2% | ||
| Q1 25 | 1.4% | -192.8% | ||
| Q4 24 | 17.1% | — | ||
| Q3 24 | 323.0% | 53.4% | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -20.8% | — |
资本支出强度CLFDDAWN
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.0% | 0.0% | ||
| Q2 25 | 0.8% | 0.0% | ||
| Q1 25 | 5.1% | 1.0% | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 71.4% | 0.8% | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 5.3% | — |
现金转化率CLFDDAWN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLFD
暂无分部数据
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
